Ferrosan

Ferrosan Medical Devices is a long-established, global leader in gelatin-based hemostatic agents and specialized biopsy systems. The company's commercial portfolio is built around three main hemostatic brands—SURGIFLO™, SURGIFOAM™, and SPONGOSTAN™—and an innovative, handheld breast biopsy device. Operating as a commercial-stage entity, Ferrosan focuses on empowering surgical teams with effective, safe tools while embedding sustainability into its core operations, as evidenced by its commitment to the UN Global Compact and recent MDR certifications.

Biomaterial-based platform utilizing absorbable porcine gelatin in sponge, powder, and flowable matrix forms, often combined with active agents like thrombin. Secondary platform in miniature electromechanical systems for biopsy devices.

Ferrosan competes in the global surgical hemostat market against major players like Johnson & Johnson (Ethicon), Baxter, Integra LifeSciences, and BD. Its niche is gelatin-based biomaterials, where it is a recognized leader. In the breast biopsy segment, it faces competition from Hologic, BD, and others, differentiating itself with a tetherless, single-insertion device.